Diuretic Combinations in Refractory Oedema States: Pharmacokinetic-Pharmacodynamic Relationships

Clinical Pharmacokinetics

Volumn 30, Issue 3, 1996, Pages 229-249

  Sica, Domenic A ^a   Gehr, Todd W B ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; DIURETIC AGENT; ELECTROLYTE; FUROSEMIDE; LOOP DIURETIC AGENT; METOLAZONE; SPIRONOLACTONE; THEOPHYLLINE; THIAZIDE DIURETIC AGENT;

ALKALOSIS; BODY WEIGHT; CHRONIC KIDNEY FAILURE; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG TRANSPORT; EDEMA; ELECTROLYTE BALANCE; HEMODYNAMICS; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; KIDNEY TUBULE; LIVER CIRRHOSIS; NEPHRON; NEPHROTIC SYNDROME; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

DIURETICS; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HUMANS; NEPHROTIC SYNDROME;

EID: 0029882414     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199630030-00004     Document Type: Article

References (132)

1. Sica DA, Gehr TWB. Diuretics in congestive heart failure. Cardiol Clin 1989; 7: 87-97
2. Epstein M, Lepp BA, Hoffman DS, et al. Potentiation of furosemide by metolazone in refractory edema. Curr Ther Res 1977; 21: 656-67
3. Gehr TWB, Sica DA. Diuretic resistance. Drug Ther 1990; 1: 95-100
4. Brater DC. Pharmacodynamic considerations in the use of diuretics. Annu Rev Pharmacol Toxicol 1983; 23: 45-62
5. Brater DC. Resistance to diuretics: mechanisms and clinical implications. Adv Nephrol 1993; 22: 349-69
6. Odlind B. Relation between renal tubular secretion and effects of five loop diuretics. J Pharmacol Exp Ther 1979; 211: 238-44
7. Burg MB. Tubular chloride transport and the mode of action of some diuretics. Kidney Int 1976; 9: 189-97
8. Boles Ponto LL, Schoenwald RD. Furosemide (frusemide): a pharmacokinetic-pharmacodynamic review (Part I). Clin Pharmacokinet 1990; 18: 381-408
9. Rose HJ, O'Malley K, Pruitt AW. Depression of renal clearance of furosemide in man by azotemia. Clin Pharmacol Ther 1976; 21: 141-6
10. Nomura A, Yasuda H, Minami M, et al. Effect of furosemide in congestive heart failure. Clin Pharmacol Ther 1981; 30: 177-82
11. Packer M, Lee WH, Yushak M, et al. Comparison of captopril and enalapril in patients with severe congestive heart failure. N Engl J Med 1986; 315: 847-53
12. Ring-Larsen H, Hendriksen JH, Wilken C, et al. Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture. BMJ 1986; 292: 1351-3
13. Redfield MM, Edwards BS, Heublein DM, et al. Restoration of renal response to atrial natriuretic peptide in experimental low-output heart failure. Am J Physiol 1989; 257: R917-23
14. Kaojarern S, Day B, Brater DC. The time course of delivery of furosemide into urine: an independent determinant of overall response. Kidney Int 1982; 22: 69-74
15. Sica DA, Ilson B, Brater DC, et al. Metolazone - its time course of delivery as a determinant of action [abstract]. Clin Res 1984; 32: 248A
16. Rane A, Villeneuve JP, Stone WJ, et al. Plasma binding and disposition of furosemide in the nephrotic syndrome and uremia. Clin Pharmacol Ther 1978; 24: 199-207
17. Sica DA, Brater DC, Centor R, et al. Metolazone-probenecid interaction in man [abstract]. Clin Res 1987; 35: 381A
18. Chennavasin P, Seiwell R, Brater DC, et al. Pharmacodynamic analysis of the furosemide-probenecid interaction in man. Kidney Int 1979; 16: 187-95
19. Brater DC, Weiwell R, Anderson S, et al. Absorption and disposition of furosemide in congestive heart failure. Kidney Int 1982; 22: 171-6
20. Wilcox CS, Mitch WE, Kelly RA, et al. Response of the kidney to furosemide. I: Effects of salt intake and renal compensation. J Lab Clin Med 1983; 102: 450-8
21. Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med 1991; 114: 886-94
22. Walter SJ, Shirley DG. The effect of chronic hydrochlorothiazide administration on renal function in the rat. Clin Sci 1986; 70: 379-87
23. Kelly RA, Wilcox CS, Mitch WE, et al. Response of the kidney to furosemide. II: Effect of captopril on sodium balance. Kidney Int 1983; 24: 233-39
24. +, and BP homeostasis in man during furosemide: effects of prazosin and captopril. Kidney Int 1987; 31: 135-41
25. Ajlstrom NG, Capraro FE, Wilcox CS. Post-diuretic salt retention in man: dissociation from volume depletion [abstract]. Kidney Int 1990; 37: 270
26. Ellison DH, Velasquez H, Wright FS. Adaptation of the distal convoluted tubule of the rat: structural and functional effects of dietary salt intake and chronic diuretic infusion. J Clin Invest 1989; 83: 113-26
27. Kaisling B, Stanton BA. Adaptation of distal tubule and collecting duct to increased sodium delivery: I. Ultrastructure. Am J Physiol 1988; 255: F1256-68
28. + transport. Am J Physiol 1988; 255: F1269-75
29. Kaissling B, Bachmann S, Kriz W. Structural adaptation of the distal convoluted tubule to prolonged furosemide treatment. Am J Physiol 1985; 248: F374-81
30. Morsing P, Velazquez H, Wright FS, et al. Adaptation of distal convoluted tubule of rats: II. Effects of chronic thiazide infusion. Am J Physiol 1991; 261: F137-43
31. Brater DC, Day B, Burdette A, et al. Bumetanide and furosemide in heart failure. Kidney Int 1984; 26: 183-9
32. Fredrick MJ, Pound DC, Hall SD, et al. Furosemide absorption in patients with cirrhosis. Clin Pharmacol Ther 1991; 49: 241-7
33. Vasko MR, Brown-Cartwright D, Knochel JP, et al. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med 1985; 102: 314-8
34. Vargo DL, Kramer WG, Black PK, et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. J Clin Pharmacol Ther 1995; 57: 601-9
35. Francis GS, Goldsmith SR, Levine TB, et al. The neurohumoral axis in congestive heart failure. Ann Intern Med 1985; 103: 1-6
36. Smith DE, Hyneck ML, Berardi RR, et al. Urinary protein binding, kinetics, and dynamics of furosemide in nephrotic patients. J Pharm Sci 1985; 74: 603-7
37. Keller E, Hoppe-Seyler G, Schollmeyer P. Disposition and diuretic effect of furosemide in nephrotic syndrome. Clin Pharmacol Ther 1982; 32: 442-9
38. Keller E, Hoppe-Seyler G, Schollmeyer P. Disposition and diuretic effects of furosemide in the nephrotic syndrome. Clin Pharmacol Ther 1982; 32: 442-9
39. Green TP, Mirkin BL. Resistance of proteinuric rats to furosemide: urinary drug protein binding as a determinant of drug effect. Life Sci 1980; 26: 623-30
40. Kirchner KA, Voelker JR, Brater DC. Intratubular albumin blunts the response to furosemide - a mechanism for diuretic resistance in the nephrotic syndrome. J Pharmacol Exp Ther 1990; 252: 1097-101
41. Kirchner KA, Voelker JR, Brater DC. Binding inhibitors restore furosemide potency in tubule fluid containing albumin. Kidney Int 1991; 40: 418-24
42. Inoue M, Okajima K, Itoh K, et al. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int 1987; 32: 198-203
43. Nakahama H, Orita Y, Yamazaki M, et al. Pharmacokinetic and pharmacodynamic interactions between furosemide and hydrochlorothiazide in nephrotic patients. Nephron 1988; 49: 223-7
44. Garin EH, Richard GA. Edema resistant to furosemide therapy in nephrotic syndrome: treatment with furosemide and metolazone. Inter J Ped Nephrol 1981; 2: 181-4
45. Kuchar DL, O'Rourke MF. High dose furosemide in refractory cardiac failure. Eur Heart J 1985; 6: 954-8
46. Gerlag PGG, van Meijel JJM. High dose furosemide in the treatment of refractory congestive heart failure. Arch Intern Med 1988; 148: 286-91
47. Rybak LP. Pathophysiology of furosemide ototoxicity. J Otolaryngol 1982; 11: 127-33
48. Quick CA, Hoppe W. Permanent deafness associated with furosemide administration. Ann Otol 1975; 84: 94-101
49. Copeland JG, Campbell DW, Plachetka JR, et al. Diuresis with continuous infusion of furosemide after cardiac surgery. Am J Surg 1983; 146: 796-9
50. Lawson DH, Gray JMB, Henry DA, et al. Continuous infusion of furosemide in refractory edema. BMJ 1978; 2: 476
51. Rudy DW, Sica DA, Nunley J, et al. Furosemide infusions in diuretic resistant individuals [abstract]. Clin Pharmacol Ther 1990; 47: 144
52. Rudy DW, Voelker JR, Greene PK, et al. Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Ann Intern Med 1991; 115: 360-6
53. GehrT, Sica DA, Brater DC, et al. Furosemide pharmacokinetics and pharmacodynamics in renal transplantation. Clin Pharmacol Ther 1988; 43: 547-53
54. Dettli L, Spring P. Therapy with combinations of diuretic agents: comparative studies. Ann NY Acad Sci 1966; 139: 471-80
55. Leiter L. Combinations of diuretics in the treatment of edema. Am Heart J 1978; 80: 422-6
56. Seller RH, Fuchs M, Swartz C, et al. Treatment of edema by the combined use of chemically different diuretic agents. Am J Cardiol 1963; 12: 828-33
57. Knauf H, Mutschler E. Low-dose segmental blockade of the nephron rather than high-dose diuretic monotherapy. Eur J Clin Pharmacol 1991; 44 Supp.1: S63-8
58. Fliser D, Schroter M, Neubeck M, et al. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int 1994; 46: 482-8
59. Olesen KH, Sigurd B. The supra-additive natriuretic effect addition of quinethazone or bendroflumethiazide during long-term treatment with furosemide and spironolactone. Acta Med Scand 1971; 190: 233-40
60. Domenet J, Evans G, Brenner O. Value of mercaptomerin and aminophylline in cardiac edema resistant to other diuretics. BMJ 1961 Apr; 22(1): 1130-9
61. Knauf H, Wenk E, Scholmerich J, et al. Prediction of diuretic mobilization of cirrhotic ascites by pretreatment fractional sodium excretion. Klin Wochenschr 1990; 68: 545-51
62. Sigurd B, Olesen KH. Comparative natriuretic and diuretic efficacy of theophylline ethylenediamine and of bendroflumethiazide during long-term treatment with the potent diuretic bumetanide. Acta Med Scand 1978; 203: 113-9
63. Maren TH. The additive renal effect of oral aminophylline and trichlormethiazide in man [abstract]. Clin Res 1961; 9: 57
64. Brater DC, Kaojerern S, Chennavasin P. Pharmacodynamics of the diuretic effects of aminophylline and acetazolamide alone and combined with furosemide in normal subjects. J Pharmacol Exp Ther 1983; 227: 92-7
65. Korzets A, Gafter K, Floru S, et al. Deteriorating renal function with acetazolamide in a renal transplant patient with pseudotumor cerebri. Am J Kidney Dis 1993; 21: 322-4
66. Khan MI. Treatment of refractory congestive heart failure and normokalemic hypochloremic alkalosis with acetazolamide and spironolactone. Can Med Assoc J 1980; 123: 883-7
67. Olesen KH. The natriuretic effect addition of quinethazone and furosemide in congestive heart failure. Acta Med Scand 1971; 190: 229-32
68. Olesen KH, Dupont B, Flensted-Jensen E. The combined diuretic action of quinethazone and furosemide in congestive heart failure: a permutation trial test. Acta Med Scand 1970; 187: 33-40
69. Sigurd B, Olesen KH, Wennevold A. The supra-additive natriuretic effect addition of bendroflumethiazide and bumetanide in congestive heart failure. Am Heart J 1975; 89: 163-70
70. Orita Y, Nakahama H, Fukuhara Y, et al. Combination diuretic therapy - furosemide with hydrochlorothiazide. In: Puschett JB, editor. Diuretics III: Chemistry, pharmacology, and clinical applications. Amsterdam: Elsevier, 1990: 3-11
71. Wollam GL, Tarazi RC, Bravo EL, et al. Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. Am J Med 1982; 72: 929-38
72. Garin EH. A comparison of combinations of diuretics in nephrotic edema. Am J Dis Child 1987; 141: 769-71
73. Oimomi M, Shigeki T, Susumu S. Combination diuretic therapy for severe refractory nephrotic syndrome. Lancet 1990; 336: 1004-4
74. Channer KS, McLean KA, Lawson-Matthew P, et al. Combination diuretic treatment in severe heart failure: a randomized clinical trial. Br Heart J 1994; 71: 146-50
75. Steinmuller SR, Puschett JB. Effects of metolazone in man: comparison with chlorothiazide. Kidney Int 1972; 1: 169-81
76. Dormans TPJ, Gerlag PGG. Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure. In: Puschett JB, editor. Diuretics. IV: Chemistry, pharmacology and clinical applications. Amsterdam: Elsevier, 1993; 45-8
77. Fernandez PC, Puschett JB. Proximal tubular actions of metolazone and chlorothiazide. Am J Physiol 1973; 225: 954-61
78. Cass n S, Vogh BP. Effect of hydrochlorothiazide on renal blood flow and clearance of para-aminohippurate and creatinine. Proc Soc Exp Biol Med 1966; 122: 970-3
79. Suki WN, Dawoud F, Eknoyan G, et al. Effects of metolazone on renal function in normal man. J Pharmacol Exp Ther 1972; 180: 6-12
80. Michelis MF, DeRubertis F, Beck NP, et al. Standard oral water load to determine the site of action of diuretics in man. Clin Pharmacol Ther 1970; 11: 821-8
81. Friedman PA. Biochemistry and pharmacology of diuretics. Semin Nephrol 1988; 8: 198-212
82. Boer W, Koomas H, Dorhout Mees E. Effect of thiazides with and without carbonic anhydrase inhibiting activity on free water and lithium clearance. In: Puschett JB, editor. Diuretics. III: Chemistry, pharmacology and clinical applications. Amsterdam: Elsevier. 1990: 31-3
83. Allen JM, Hind CRK, McMichael HB. Synergistic action of me olazone with 'loop' diuretics [letter]. BMJ 1981; 282: 1873
84. Arnold WC. Efficacy of metolazone and furosemide in children with furosemide-resistant edema. Pediatrics 1984; 74: 872-5
85. Asscher AW. Treatment of frusemide resistant oedema with metolazone. Clin Trials J 1974; 11: 134-9
86. Bamford JM. Synergistic action of metolazone with 'loop' diuretics [letter]. BMJ 1981; 283: 618
87. Black WD, Shiner PT, Roman J. Severe electrolyte disturbances associated with metolazone and furosemide. South Med J 1978; 71: 380-2
88. Brater DC, Pressley RH, Anderson SA. Mechanisms of the synergistic combination of metolazone and bumetanide. J Pharmacol Exp Ther 1985; 233: 70-4
89. Brown E, MacGregor G. Synergistic action of metolazone and frusimide [letter]. BMJ 1981; 283: 1611
90. Craswell PW, Ezzat E, Kopstein J, et al. Use of metolazone, a new diuretic, in patients with renal disease. Nephron 1973; 12: 63-73
91. Furniss L, Elenbaas J. Metolazone-furosemide synergism. Drug Intel Clin Pharm 1980; 14: 842-3
92. Furrer J, Hess OM, Kuhlmann U, et al. Furosemide and metolazone: a highly effective diuretic combination. Schweiz Med Wschr 1980; 110: 1825-9
93. Gage JS, Mancini DM, Gumbardo W, et al. Efficacy of combined diuretic therapy with metolazone and furosemide in patients with refractory congestive heart failure. Cardiovasc Rev Rep 1986; 7: 814-7
94. Ghose RR, Gupta SK. Synergistic action of metolazone with 'loop' diuretics. BMJ 1981; 282: 1432-3
95. Grosskopf I, Rabinovitz M, Rosenfeld JB. Combination of furosemide and metolazone in the treatment of severe congestive heart failure. Isr J Med Sci 1986; 22: 787-90
96. Gunstone RF, Wing AJ, Shani HGP, et al. Clinical experience with metolazone in fifty-two African patients: synergy with frusemide. Postgrad Med J 1971; 47: 789-93
97. Kshinsagar NA, Gupta KC, Paul T, et al. Effect of metolazone addition on furosemide resistant cases of edema. J Assoc Phys India 1978; 26: 915-23
98. Hropot M, Sorgel F, Mutshler E. Pharmacodynamics and pharmacokinetics of furosemide combinations with potassium-retaining and thiazide-like diuretics: clearance and micropuncture studies. Arch Pharmacol 1986; 333: 457-61
99. + reabsorption by lithium clearance in nephrotic patients. In: Puschett JB, editor. Diuretics. III: Chemistry, pharmacology and clinical applications. Amsterdam: Elsevier, 1990; 38-40
100. Marone C, Muggli CMF, Lahn W, et al. Pharmacokinetic and pharmacodynamic interaction between furosemide and metolazone in man. Eur J Clin Invest 1985; 15: 253-7
101. Oster JR, Epstein M, Smoller S. Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention. Ann Intern Med 1983; 99: 405-6
102. Ram CVS, Reichgott MJ. Treatment of loop-diuretic resistant edema by the addition of metolazone. Curr Ther Res 1977; 22: 686-91
103. Kiyingi A, Field MJ, Pawsey CC, et al. Metolazone in treatment of severe refractory congestive cardiac failure. Lancet 1990; 335: 29-31
104. Segar JL, Robillard JE, Johnson KJ, et al. Addition of metolazone to overcome tolerance to furosemide in infants with bronchopulmonary dysplasia. J Pediatr 1992; 120: 966-73
105. Cachero SD, Lofland G, Springate JE, et al. Combination of metolazone and furosemide in the treatment of edema in the first month of life. Child Nephrol Urol 1990; 10: 161-3
106. Garin EH, Richard GA. Metolazone and furosemide for edema. Pediatrics 1986; 77: 130-1
107. Aravot DJ, Banner NR, Musumeci F, et al. Oral metolazone plus frusemide for home therapy in patients with refractory heart failure. Lancet 1989; 333: 727-8
108. Farthing D, Sica DA, Fakhry I, et al. A novel HPLC method using solid phase on-line elution for determination of metolazone in plasma and whole blood. J Chromatogr Biomed Appl 1994; 653: 171-6
109. Sica DA, Gehr TWB. Diuretic use in end-stage renal disease. Semin Dial 1995; 8: 305-10
110. Egel J, Pfansteil J, Puschett J. Diuretic effects on renal brush border membrane transport and metabolism. Life Sci 1985; 37: 1675-81
111. Kempson SA, Kowalski JC, Puschett J. Direct effect of metolazone on sodium-dependent transport across the renal brush border membrane. J Lab Clin Med 1983; 101: 308-16
112. Belair EJ, Cohen AL, Yelnosky J. Renal excretion of metolazone, a new diuretic. Br J Pharmacol 1972; 45: 476-9
113. Tilstone WJ, Dargie H, Dargie EN, et al. Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure. Clin Pharmacol Ther 1974; 16: 322-9
114. 14C-metolazone, in dogs. J Pharm Sci 1973; 62: 931-6
115. 14C-Zaroxylyn™, a new diuretic, to blood fractions and the pattern of metabolites in man and other species [abstract]. Proc Can Fed Biol Sci 1970; 13: 155
116. 14C-counting techniques [abstract]. Fed Proc 1970; 29: 276
117. Curry CL, Janda SM, Harris R, et al. Clinical studies of a new, low-dose formulation of metolazone for the treatment of hypertension. Clin Ther 1986; 9: 47-62
118. Dargie HJ, Allison MEM, Kennedy AC, et al. Efficacy of metolazone in patients with renal edema. Clin Nephrol 1974; 2: 157-60
119. Paton RR, Kane RE. Long-term diuretic therapy with metolazone of renal failure and the nephrotic syndrome. J Clin Pharmacol 1977; 17: 243-51
120. Schonees R, Mostert JW, Moore RH. Evaluation of metolazone, new diuretic in chronic renal disease. NY State J Med 1971; 71: 566-9
121. Reubi FC, Cottier PT. Effect of reduced glomerular filtration rate on responsiveness to chlorothiazide and mercurial diuretics. Circulation 1961; 23: 200-10
122. Lowenthal DT, Shear L. Use of a new diuretic agent (metolazone) in patients with edema and ascites. Arch Intern Med 1973; 132: 38-41
123. Hillenbrand P, Sherlock S. Use of metolazone in the treatment of ascites due to liver disease. BMJ 1971; 4: 266-70
124. Lang GR, Westenfelder C, Nascimento L. Metolazone and spironolactone in cirrhosis and the nephrotic syndrome. Clin Pharmacol Ther 1977; 21: 234-43
125. Bennett WM, Porter GA. Efficacy and safety of metolazone in renal failure and the nephrotic syndrome. J Clin Pharmacol 1973; 13: 357-64
126. Chemtob S, Kaplan BS, Sherbotie JR, et al. Pharmacology of diuretics in the newborn. Pediatr Clin North Am 1989; 36: 1231-50
127. Mirochnick MH, Micelli JJ, Kramer PA, et al. Furosemide pharmacokinetics in very low birth weight infants. J Pediatr 1988; 112: 653-7
128. Peterson RG, Simmons MA, Rumack BH, et al. Pharmacology of furosemide in the premature newborn infant. J Pediatr 1980; 97: 139-43
129. Vert P, Broquaire M, Legagneur M, et al. Pharmacokinetics of furosemide in neonates. Eur J Clin Pharmacol 1982; 22: 39-45
130. Chemtob S, Papageorgiou A, du Sonich P, et al. Cumulative increase in serum furosemide concentration following repeated doses in the newborn. Am J Perinatol 1987; 4: 203-5
131. Aranda JV, Turmen T, Sasyniuk BI. Pharmacokinetics of diuretics and methylxanthines in the neonate. Eur J Clin Pharmacol 1980; 18: 55-63
132. Whang R, Whang DD, Ryan MP. Refractory potassium depletion: a consequence of magnesium deficiency. Arch Int Med 1992; 152: 40-5